A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations containing alum increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection in mice

In this work, we evaluated recombinant receptor binding domain (RBD)-based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus alum, AddaS03, AddaVax, or the combination of alum and U-Omp19: a novel Brucella spp. prot...

Descripción completa

Detalles Bibliográficos

Autores principales:	Coria, Lorena M., Saposnik, Lucas M., Pueblas Castro, Celeste, Castro, Eliana Florencia, Bruno, Laura A., Stone, William B., Pérez, Paula S., Darriba, Maria Laura, Chemes, Lucia B., Alcain, Julieta, Mazzitelli, Ignacio, Varese, Augusto, Salvatori, Melina, Auguste, Albert J., Álvarez, Diego E., Pasquevich, Karina A., Cassataro, Juliana
Formato:	info:ar-repo/semantics/artículo
Lenguaje:	Inglés
Publicado:	Frontiers Media 2024
Materias:	Vaccine Adjuvants Proteinase Inhibitors Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Mice Coadyuvantes de Vacunas Inhibidores de Proteinasas Coronavirus del Síndrome Respiratorio Agudo Grave 2 Anticuerpos Ratón Germinal Center Cells Células del Centro Germinal
Acceso en línea:	http://hdl.handle.net/20.500.12123/16609 https://www.frontiersin.org/articles/10.3389/fimmu.2022.844837/full https://doi.org/10.3389/fimmu.2022.844837